Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jacobio Pharmaceuticals has recently showcased promising clinical data at the 2024 ASCO Annual Meeting, indicating significant treatment efficacy of its novel combination therapy for non-small cell lung cancer (NSCLC). The company’s KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312, demonstrated a high objective response and disease control rate, with a manageable safety profile. This milestone has led to the initiation of a Phase III trial in China, and the monotherapy has received Priority Review by China’s drug regulatory authority.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.